12/4
08:46 am
glmd
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH [Yahoo! Finance]
Medium
Report
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH [Yahoo! Finance]
12/4
08:30 am
glmd
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Low
Report
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
12/1
08:30 am
glmd
Galmed Issues CEO Letter to Shareholders
Low
Report
Galmed Issues CEO Letter to Shareholders
11/26
08:30 am
glmd
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
11/18
08:30 am
glmd
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Medium
Report
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
11/17
09:22 am
glmd
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro [Yahoo! Finance]
High
Report
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro [Yahoo! Finance]
11/17
08:30 am
glmd
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
High
Report
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro